SA author Stephen Simpson says J&J (JNJ -0.7%) had a decent Q2, with an encouraging...

|By:, SA News Editor

SA author Stephen Simpson says J&J (JNJ -0.7%) had a decent Q2, with an encouraging underlying performance in the company's drug and orthopedics ops. Simpson's main concern is the devices and diagnostics arms, the latter seeming to be slipping "further and further behind." Still, J&J "looks like a worthwhile name for conservative investors looking for healthcare exposure."